Results 211 to 220 of about 744,871 (360)
Activation of the Insulin Receptor by <i>Sarcopoterium spinosum</i> Extract and Identification of Sarcocyanidin A as a Novel Active Compound. [PDF]
Wollman A+3 more
europepmc +1 more source
This study identifies ARID1B as a chromatin‐bound driver of tumor growth in TNBC. ARID1B impairs ARID1A function and directly activates oncogenic programs through SWI/SNF remodeling. Its nuclear localization, mediated by the KPNA2–KPNB1–RANBP2 import machinery, is essential for its tumor‐promoting activity.
Olena Odnokoz+14 more
wiley +1 more source
TRIM32 regulates insulin sensitivity by controlling insulin receptor degradation in the liver. [PDF]
Thakur S, Rawat P, Dehury B, Mondal P.
europepmc +1 more source
This study develops an a red/far‐red light‐controlled iPSC‐based vaccines (RIVA) based on the chimeric photosensory protein FnBphP and its interaction partner LDB3 for cancer immunotherapy. The RIVA preserves the multiple intrinsic tumor antigens of iPSCs and enables optogenetic control of the expression of the immune adjuvant type I interferon β under
Longliang Qiao+17 more
wiley +1 more source
Targeting of loaded Sendai virus envelopes by covalently attached insulin molecules to virus receptor-depleted cells: fusion-mediated microinjection of ricin A and simian virus 40 DNA. [PDF]
A G Gitman+2 more
openalex +1 more source
Worse survival of hepatocellular cancer patients with membranous insulin receptor overexpression. [PDF]
Heckl SM+12 more
europepmc +1 more source
SIRT3 expression is significantly downregulated in the aged kidney, rendering the kidney more vulnerable to fibrotic changes in obstructive nephropathy. By promoting GSK‐3β deacetylation, SIRT3 indirectly inhibits Wnt/β‐catenin signaling, thereby suppressing renal fibrosis.
Jing Wang+11 more
wiley +1 more source
Impaired insulin receptor function alters psychiatric behaviors without affecting circadian rhythms in a mouse model of Alzheimer's disease. [PDF]
Izuo N, Yokote K, Shimizu T.
europepmc +1 more source
This study identifies α‐Hederin as a potent dual JAK1/JAK2 inhibitor that blocks STAT3 activation in ovarian cancer. By disrupting STAT3‐driven transcriptional programs, α‐Hederin suppresses tumor proliferation, invasion, and EMT, while enhancing cisplatin efficacy and overcoming chemoresistance.
Jiayu Wang+9 more
wiley +1 more source